Rice Hall James & Associates LLC Grows Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Rice Hall James & Associates LLC boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 13.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 70,595 shares of the company’s stock after acquiring an additional 8,144 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Omnicell were worth $3,143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of OMCL. Van ECK Associates Corp grew its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares in the last quarter. KBC Group NV grew its position in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after purchasing an additional 778 shares in the last quarter. 1620 Investment Advisors Inc. grew its position in shares of Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares in the last quarter. CIBC Asset Management Inc purchased a new position in shares of Omnicell during the 4th quarter valued at $201,000. Finally, Summit Global Investments purchased a new position in shares of Omnicell during the 3rd quarter valued at $221,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Up 0.9 %

Shares of NASDAQ:OMCL opened at $39.97 on Wednesday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The firm has a fifty day moving average of $43.49 and a 200 day moving average of $43.90. The firm has a market capitalization of $1.85 billion, a PE ratio of 148.04, a price-to-earnings-growth ratio of 7.52 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of recent analyst reports. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Benchmark restated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Craig Hallum boosted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Barclays upped their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $52.33.

Insiders Place Their Bets

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.64% of the stock is currently owned by insiders.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.